home / stock / vcnx / vcnx news


VCNX News and Press, Vaccinex Inc. From 04/03/23

Stock Information

Company Name: Vaccinex Inc.
Stock Symbol: VCNX
Market: NASDAQ
Website: vaccinex.com

Menu

VCNX VCNX Quote VCNX Short VCNX News VCNX Articles VCNX Message Board
Get VCNX Alerts

News, Short Squeeze, Breakout and More Instantly...

VCNX - Vaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical Programs

Expect to complete patient enrollment in the randomized Phase 1/2a SIGNAL-AD Alzheimer’s study in April 2023 with topline data anticipated mid-2024 Completed enrollment of 36 patients required for a pre-planned interim analysis of KEYNOTE B84 phase 1b/2 study in Head and Neck Squam...

VCNX - Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference

ROCHESTER, N.Y., March 23, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX, “Vaccinex”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced its COO and S...

VCNX - Vaccinex starts trial of pepinemab, Bavencio combo to treat pancreatic cancer

2023-03-21 12:51:16 ET Vaccinex ( NASDAQ: VCNX ) said a phase 1b/2 trial of pepinemab in combination with avelumab as second line combination immunotherapy for patients with metastatic pancreatic adenocarcinoma (PDAC) has started. The main goal of the trial is to investiga...

VCNX - Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

The study is intended to assess whether pepinemab can reverse the suppressive tumor microenvironment found in PDAC, thereby facilitating the anti-tumor activity of immune checkpoint blockade This Vaccinex-sponsored study will be conducted at the University of Rochester Primary fun...

VCNX - Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis

Interim analysis will be performed when the last of these patients has completed a tumor assessment scan approximately 9 weeks after initiating treatment The open-label Phase 1b/2 KEYNOTE B-84 study is evaluating the use of pepinemab in combination with Merck’s KEYTRUDA ( pem...

VCNX - 7 Penny Stocks To Watch With Big News In February; Time To Buy?

Penny Stock News and Investing: Staying Informed To Make Better Decisions Whether you’re trading penny stocks or high-priced names like Apple or Amazon, staying informed about the latest news and events helps. News provides valuable insights into market trends, economic conditions,...

VCNX - Why Is Rubius Therapeutics (RUBY) Stock Down 16% Today?

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: arfa adam / Shutterstock.com Rubius Therapeutics (NASDAQ: RUBY ) stock is falling hard on Tuesday after the biotechnology company received a Nasdaq delisting notice . According to a filing with the U.S. S...

VCNX - Why Is Bed Bath & Beyond (BBBY) Stock Down 32% Today?

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: QualityHD / Shutterstock.com Bed Bath & Beyond (NASDAQ: BBBY ) stock is falling on Tuesday after the retailer revealed plans to raise about $1 billion . That plan from the company includes the sale of...

VCNX - Why Is Oak Street Health (OSH) Stock Up 36% Today?

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Jonathan Weiss / Shutterstock.com Oak Street Health (NYSE: OSH ) stock is on the rise Tuesday as investors react to a report that CVS (NYSE: CVS ) plans to take over the company. According to these r...

VCNX - Why Is Vaccinex (VCNX) Stock Up 67% Today?

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: shutterstock.com/PhotobyTawat Vaccinex (NASDAQ: VCNX ) stock is rocketing higher on Tuesday despite a lack of news from the clinical-stage biotechnology company. Instead, it looks like today’s gains...

Previous 10 Next 10